Although the determination of serum CEA concentration in cancer patients is still debated and not yet included in clinical practice guidelines, studies have shown that lower baseline CEA levels are associated with better outcomes in patients receiving immunotherapy. This evidence concerns the gene CEACAM5 and cancer.